Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

ce, they have published successful results of a Phase II clinical trial in ear infections (otitis externa) using NCT. NovaBay expects Alcon, its licensee for the use of Aganocide compounds in the treatment of eye, ear, and sinus infections, to start human trials in the ear during 2009 with NovaBay's lead Aganocide compound NVC-422. Professors Nagl and Gottardi have also pursued studies with NCT in additional indications that can provide NovaBay with guidance in its future clinical programs.

In addition to the research agreement, NovaBay has obtained an exclusive license to a broad portfolio of intellectual property covering uses of NCT compounds. As a result, NovaBay has augmented its composition of matter patent for Aganocide compounds with a license to a series of patents covering key potential uses, including utility of NCT compounds in pulmonary diseases and their potential use in major animal health markets, such as mastititis.

"We are very excited to collaborate with this world-class research team, and pleased to draw on the extensive experience of Professors Gottardi and Nagl in understanding the role of our class of molecules in the prevention and treatment of infectious diseases," said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay. "We look forward to building on their work to further expand the range of clinical opportunities provided by our Aganocide compound platform."

"We expect to substantially broaden NovaBay's efforts by leveraging the resources and expertise at the Medical University of Innsbruck," said Dr. Bez Khosrovi, Vice President of Research and Development at NovaBay. "We see this collaboration as adding significant depth to our preclinical and clinical development programs and to the continued exploration of the properties of our Aganocide compounds. We expect that our joint efforts will provide important information that may further accelerate our efforts to develop
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Radiation Oncology Solutions announced that it has ... medical linear accelerators at the John Theurer ... N.J. (Logo: http://photos.prnewswire.com/prnh/20101028/NE90717LOGO) ... which Varian designed to treat a moving ...
... YORK, Nov. 8, 2010 Reportlinker.com announces ... available in its catalogue: ... platforms, key players, and early pipeline candidates ... Therapeutic vaccines promise a new ...
Cached Medicine Technology:D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center 2D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 2Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 4Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 5Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 6Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 7Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 8Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 9
(Date:7/12/2014)... 12, 2014 Casinos in ... rising competition from international and online casinos. Revenue is ... the five years through 2014-15. Greater per capita gambling ... gaming services. Rises in discretionary income levels have also ... on non-essential items such as casino gambling services. Revenue ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
Breaking Medicine News(10 mins):Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Multi-year contract provides IP VPN service to eight sites nationwide, - Triples ... legacy ... solution, ROCHESTER, N.Y., ... provider of managed voice and data,networking solutions for businesses, today announced a ...
... Wash. March 17, 2008 The International Neuroinformatics ... Science announced today that the INCF will contribute infrastructure ... Institutes Allen Brain AtlasMouse Brain. Publicly available for ... Brain AtlasMouse Brain is a Web-based, genome-wide map of ...
... discovered what chemical in the eye triggers the dormant ... cells, a stem-like cell that can generate new retinal ... Investigative Ophthalmology and Visual Science (IOVS), offers new hope ... as macular degeneration and retinitis pigmentosa. , This ...
... On The Go,Healthcare, Inc. (OTC Bulletin Board: ... software and systems integrator,announced today that after more ... has sold its Value Added Reseller (,VAR,),business unit ... Board: FLIP). The,terms of the sale, in the ...
... from North Carolina State University have shown that silencing ... harmful carcinogens in cured tobacco leaves. , The finding ... with reduced amounts of cancer-causing agents. , NC ... Dr. Ramsey Lewis, assistant professor of crop science, teamed ...
... Neuroethics, in March 2008. Appearing three times a year, it ... related issues in the sciences of the mind. Springer ... all articles during 2008 and 2009. , Neuroethics will be ... the neuroscience of ethics. The journal will be highly ...
Cached Medicine News:Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 2Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 3Health News:INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 2Health News:INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 3Health News:Scientists successfully awaken sleeping stem cells 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Gene 'knockout' floors tobacco carcinogen 2Health News:Springer to publish new journal focusing on ethical issues in neuroscience 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: